Equities researchers at Aegis raised their target price on shares of Trius Therapeutics (NASDAQ: TSRX) from $14.00 to $18.00 in a report issued on Monday. The firm currently has a “buy” rating on the stock.
Please NO MORE GOOD NEWS! I can't take it anymore. We're liable to drop another 10% Kitty where has all that butt cream gone when you need it? I had Brandon clean out the pantry to make room for champagne bottles that I'm drinking by myself. Success is always such a disappointment. Bottom's up!